Not recommended, and no clinical evidence supports concurrent or closely sequential use. Both medicines affect serotonin systems. Ibogaine’s hERG channel blockade creates cardiac risk; ayahuasca’s MAOI activity creates serotonergic risk (Koenig et al., 2014; Callaway and Grob, 1998). Together, the compounded pharmacological load is unpredictable. If a sequential protocol is being considered, this should only occur under medical supervision with substantial time between sessions.
